Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies

Immune checkpoint inhibitors (ICI) therapy based on programmed cell death-1 (PD-1) and programmed cell death ligand 1 (PD-L1) has changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) and improved the survival expectancy of patients. However, it also leads to immune-related a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xinyu, Chen, Shi, Wang, Xueyan, Liu, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110908/
https://www.ncbi.nlm.nih.gov/pubmed/37081866
http://dx.doi.org/10.3389/fimmu.2023.1138483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110908/
https://www.ncbi.nlm.nih.gov/pubmed/37081866
http://dx.doi.org/10.3389/fimmu.2023.1138483

Ejemplares similares